These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 21328434)

  • 1. Evaluation of empiric versus nomogram-based direct thrombin inhibitor management in patients with suspected heparin-induced thrombocytopenia.
    Kiser TH; Mann AM; Trujillo TC; Hassell KL
    Am J Hematol; 2011 Mar; 86(3):267-72. PubMed ID: 21328434
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of bivalirudin and argatroban for the management of heparin-induced thrombocytopenia.
    Skrupky LP; Smith JR; Deal EN; Arnold H; Hollands JM; Martinez EJ; Micek ST
    Pharmacotherapy; 2010 Dec; 30(12):1229-38. PubMed ID: 21114390
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development and implementation of a nurse-driven, sliding-scale nomogram for bivalirudin in the management of heparin-induced thrombocytopenia.
    Burcham PK; Abel EE; Gerlach AT; Murphy CV; Belcher M; Blais DM
    Am J Health Syst Pharm; 2013 Jun; 70(11):980-7. PubMed ID: 23686604
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Weight-based argatroban dosing nomogram for treatment of heparin-induced thrombocytopenia.
    Ansara AJ; Arif S; Warhurst RD
    Ann Pharmacother; 2009 Jan; 43(1):9-18. PubMed ID: 19126826
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of argatroban and bivalirudine in patients with suspected heparin-induced thrombocytopenia.
    Vo QA; Lin JK; Tong LM
    Ann Pharmacother; 2015 Feb; 49(2):178-84. PubMed ID: 25515865
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of 2 nomogram-based strategies for dosing argatroban in patients with known or suspected heparin-induced thrombocytopenia.
    Arpino PA; Goeller AJ; Fatalo A; Van Cott EM
    Clin Appl Thromb Hemost; 2015 Apr; 21(3):260-5. PubMed ID: 23965335
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation of bivalirudin dose with creatinine clearance during treatment of heparin-induced thrombocytopenia.
    Runyan CL; Cabral KP; Riker RR; Redding D; May T; Seder DB; Savic M; Hedlund J; Abramson S; Fraser GL
    Pharmacotherapy; 2011 Sep; 31(9):850-6. PubMed ID: 21923585
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of bivalirudin to lepirudin and argatroban in patients with heparin-induced thrombocytopenia.
    Bain J; Meyer A
    Am J Health Syst Pharm; 2015 Sep; 72(17 Suppl 2):S104-9. PubMed ID: 26272889
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of treatment with direct thrombin inhibitors in patients with heparin-induced thrombocytopenia.
    Dang CH; Durkalski VL; Nappi JM
    Pharmacotherapy; 2006 Apr; 26(4):461-8. PubMed ID: 16553503
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and effectiveness outcomes of an inpatient collaborative drug therapy management service for direct thrombin inhibitors.
    Cooper T; White CL; Taber D; Uber WE; Kokko H; Mazur J
    Am J Health Syst Pharm; 2012 Nov; 69(22):1993-8. PubMed ID: 23135566
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monitoring of Argatroban and Lepirudin: What is the Input of Laboratory Values in "Real Life"?
    Seidel H; Kolde HJ
    Clin Appl Thromb Hemost; 2018 Mar; 24(2):287-294. PubMed ID: 28320219
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of bivalirudin dosing strategies using total, adjusted, and ideal body weights in obese patients with heparin-induced thrombocytopenia.
    Tsu LV; Dager WE
    Pharmacotherapy; 2012 Jan; 32(1):20-6. PubMed ID: 22392825
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of a standardized protocol using lepirudin or argatroban for heparin-induced thrombocytopenia.
    Kennedy K; Steinke D; King S; Poe K; Reeves J; Short M
    Cardiovasc Hematol Agents Med Chem; 2011 Oct; 9(4):262-8. PubMed ID: 21902659
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bivalirudin dosing adjustments for reduced renal function with or without hemodialysis in the management of heparin-induced thrombocytopenia.
    Tsu LV; Dager WE
    Ann Pharmacother; 2011 Oct; 45(10):1185-92. PubMed ID: 21881032
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Argatroban versus Lepirudin in critically ill patients (ALicia): a randomized controlled trial.
    Treschan TA; Schaefer MS; Geib J; Bahlmann A; Brezina T; Werner P; Golla E; Greinacher A; Pannen B; Kindgen-Milles D; Kienbaum P; Beiderlinden M
    Crit Care; 2014 Oct; 18(5):588. PubMed ID: 25344113
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of bivalirudin treatment for heparin-induced thrombocytopenia in critically ill patients with hepatic and/or renal dysfunction.
    Kiser TH; Fish DN
    Pharmacotherapy; 2006 Apr; 26(4):452-60. PubMed ID: 16553502
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety, efficacy, and dosing requirements of bivalirudin in patients with heparin-induced thrombocytopenia.
    Kiser TH; Burch JC; Klem PM; Hassell KL
    Pharmacotherapy; 2008 Sep; 28(9):1115-24. PubMed ID: 18752382
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Successful use of a bivalirudin treatment protocol to prevent extracorporeal thrombosis in ambulatory hemodialysis patients with heparin-induced thrombocytopenia.
    Al-Ali FS; Elsayed M; Khalifa S; Abdulla AE; Tolba H; Bouanane H; Ibrahim R; Hamad A
    Hemodial Int; 2016 Apr; 20(2):204-7. PubMed ID: 26501237
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of critical illness and organ failure on therapeutic argatroban dosage requirements in patients with suspected or confirmed heparin-induced thrombocytopenia.
    Keegan SP; Gallagher EM; Ernst NE; Young EJ; Mueller EW
    Ann Pharmacother; 2009 Jan; 43(1):19-27. PubMed ID: 19116377
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of diagnostic tests and argatroban or lepirudin therapy in patients with suspected heparin-induced thrombocytopenia.
    Kiser TH; Jung R; MacLaren R; Fish DN
    Pharmacotherapy; 2005 Dec; 25(12):1736-45. PubMed ID: 16305293
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.